1、Xu S, Moss TJ, Laura Rubin M, et al. Whole-exome sequencing for
ocular adnexal sebaceous carcinoma suggests PCDH15 as a novel
mutation associated with metastasis[ J]. Mod Pathol, 2020, 33(7):
1256-1263.Xu S, Moss TJ, Laura Rubin M, et al. Whole-exome sequencing for
ocular adnexal sebaceous carcinoma suggests PCDH15 as a novel
mutation associated with metastasis[ J]. Mod Pathol, 2020, 33(7):
1256-1263.
2、Tetzlaff MT, Singh RR, Seviour EG, et al. Next-generation sequencing
identifies high frequency of mutations in potentially clinically actionable
genes in sebaceous carcinoma[ J]. J Pathol, 2016, 240(1): 84-95.Tetzlaff MT, Singh RR, Seviour EG, et al. Next-generation sequencing
identifies high frequency of mutations in potentially clinically actionable
genes in sebaceous carcinoma[ J]. J Pathol, 2016, 240(1): 84-95.
3、North JP, Golovato J, Vaske CJ, et al. Cell of origin and mutation pattern
define three clinically distinct classes of sebaceous carcinoma[ J]. Nat
Commun, 2018, 9(1): 1894.North JP, Golovato J, Vaske CJ, et al. Cell of origin and mutation pattern
define three clinically distinct classes of sebaceous carcinoma[ J]. Nat
Commun, 2018, 9(1): 1894.
4、North JP, Solomon DA, Golovato J, et al. Loss of ZNF750 in ocular
and cutaneous sebaceous carcinoma[ J]. J Cutan Pathol, 2019,
46(10): 736-741.North JP, Solomon DA, Golovato J, et al. Loss of ZNF750 in ocular
and cutaneous sebaceous carcinoma[ J]. J Cutan Pathol, 2019,
46(10): 736-741.
5、Tetzlaff MT, Curry JL, Ning J, et al. Distinct biological types of ocular
adnexal sebaceous carcinoma: HPV-driven and virus-negative tumors
arise through nonoverlapping molecular-genetic alterations[ J]. Clin
Cancer Res, 2019, 25(4): 1280-1290.Tetzlaff MT, Curry JL, Ning J, et al. Distinct biological types of ocular
adnexal sebaceous carcinoma: HPV-driven and virus-negative tumors
arise through nonoverlapping molecular-genetic alterations[ J]. Clin
Cancer Res, 2019, 25(4): 1280-1290.
6、Esmaeli B, Nasser QJ, Cruz H, et al. American Joint Committee on
Cancer T category for eyelid sebaceous carcinoma correlates with nodal
metastasis and survival[ J]. Ophthalmology, 2012, 119(5): 1078-1082.Esmaeli B, Nasser QJ, Cruz H, et al. American Joint Committee on
Cancer T category for eyelid sebaceous carcinoma correlates with nodal
metastasis and survival[ J]. Ophthalmology, 2012, 119(5): 1078-1082.
7、Zhou C, Shi Y, Chai P, et al. Contemporary update of overall prognosis
and nomogram to predict individualized survival for Chinese patients
with eyelid sebaceous carcinoma[ J]. EBioMedicine, 2018, 36: 221-228.Zhou C, Shi Y, Chai P, et al. Contemporary update of overall prognosis
and nomogram to predict individualized survival for Chinese patients
with eyelid sebaceous carcinoma[ J]. EBioMedicine, 2018, 36: 221-228.
8、中华医学会眼科学分会眼整形眼眶病学组. 我国睑板腺癌临床
诊疗专家共识(2017年)[ J]. 中华眼科杂志, 2017, 53(6): 413-415.
Oculoplastic and Orbital Disease Group, Chinese Ophthalmological
Society. Consensus in clinical diagnosis and treatment of sebaceous cell
carcinoma in China (2017)[ J]. Chinese Journal of Ophthalmology,
2017, 53(6): 413-415.中华医学会眼科学分会眼整形眼眶病学组. 我国睑板腺癌临床
诊疗专家共识(2017年)[ J]. 中华眼科杂志, 2017, 53(6): 413-415.
Oculoplastic and Orbital Disease Group, Chinese Ophthalmological
Society. Consensus in clinical diagnosis and treatment of sebaceous cell
carcinoma in China (2017)[ J]. Chinese Journal of Ophthalmology,
2017, 53(6): 413-415.
9、Sa HS, Tetzlaff MT, Esmaeli B, et al. Predictors of local recurrence for
eyelid sebaceous carcinoma: questionable value of routine conjunctival
map biopsies for detection of pagetoid spread[ J]. Ophthalmic Plast
Reconstr Surg, 2019, 35(5): 419-425.Sa HS, Tetzlaff MT, Esmaeli B, et al. Predictors of local recurrence for
eyelid sebaceous carcinoma: questionable value of routine conjunctival
map biopsies for detection of pagetoid spread[ J]. Ophthalmic Plast
Reconstr Surg, 2019, 35(5): 419-425.
10、Kaliki S, Morawala A, Dharap RS, et al. Pagetoid tumour spread in
periocular sebaceous gland carcinoma: a comparative analysis in 130
patients[ J]. Eye (Lond), 2021, 35(10): 2864-2870.Kaliki S, Morawala A, Dharap RS, et al. Pagetoid tumour spread in
periocular sebaceous gland carcinoma: a comparative analysis in 130
patients[ J]. Eye (Lond), 2021, 35(10): 2864-2870.
11、Sa HS, Rubin ML, Xu S, et al. Prognostic factors for local recurrence,
metastasis and survival for sebaceous carcinoma of the eyelid: observations
in 100 patients[J]. Br J Ophthalmol, 2019, 103(7): 980-984.Sa HS, Rubin ML, Xu S, et al. Prognostic factors for local recurrence,
metastasis and survival for sebaceous carcinoma of the eyelid: observations
in 100 patients[J]. Br J Ophthalmol, 2019, 103(7): 980-984.
12、Owen JL, Kibbi N, Worley B, et al. Sebaceous carcinoma: evidencebased clinical practice guidelines[ J]. Lancet Oncol, 2019, 20(12):
e699-e714.Owen JL, Kibbi N, Worley B, et al. Sebaceous carcinoma: evidencebased clinical practice guidelines[ J]. Lancet Oncol, 2019, 20(12):
e699-e714.
13、Zhou C, Wu F, Chai P, et al. Mohs micrographic surgery for eyelid
sebaceous carcinoma: A multicenter cohort of 360 patients[ J]. J Am
Acad Dermatol, 2019, 80(6): 1608-1617.e1.Zhou C, Wu F, Chai P, et al. Mohs micrographic surgery for eyelid
sebaceous carcinoma: A multicenter cohort of 360 patients[ J]. J Am
Acad Dermatol, 2019, 80(6): 1608-1617.e1.
14、Sargen MR, Cahoon EK, Lynch CF, et al. Sebaceous carcinoma incidence
and survival among solid organ transplant recipients in the United States,
1987-2017[ J]. JAMA Dermatol, 2020, 156(12): 1307-1314.Sargen MR, Cahoon EK, Lynch CF, et al. Sebaceous carcinoma incidence
and survival among solid organ transplant recipients in the United States,
1987-2017[ J]. JAMA Dermatol, 2020, 156(12): 1307-1314.
15、Ferreira I, Wiedemeyer K, Demetter P, et al. Update on the pathology,
genetics and somatic landscape of sebaceous tumours. Histopathology.
2020;76(5):640-649.Ferreira I, Wiedemeyer K, Demetter P, et al. Update on the pathology,
genetics and somatic landscape of sebaceous tumours. Histopathology.
2020;76(5):640-649.
16、Reuben A, Petaccia de Macedo M, McQuade J, et al. Comparative
immunologic characterization of autoimmune giant cell myocarditis
with ipilimumab[ J]. Oncoimmunology, 2017, 6(12): e1361097.Reuben A, Petaccia de Macedo M, McQuade J, et al. Comparative
immunologic characterization of autoimmune giant cell myocarditis
with ipilimumab[ J]. Oncoimmunology, 2017, 6(12): e1361097.
17、Saliba M, Shaheen M, Hajj RE, et al. PD-L1 expression in sebaceous
carcinomas. Cancer Immunol Immunother. 2021;70(7):1907-1915.Saliba M, Shaheen M, Hajj RE, et al. PD-L1 expression in sebaceous
carcinomas. Cancer Immunol Immunother. 2021;70(7):1907-1915.
18、Xu S, Yu H, Fu G, et al. Programmed death receptor Ligand 1
expression in eyelid sebaceous carcinoma: a consecutive case series of
41 patients[ J]. Acta Ophthalmol, 2019, 97(3): e390-e396.Xu S, Yu H, Fu G, et al. Programmed death receptor Ligand 1
expression in eyelid sebaceous carcinoma: a consecutive case series of
41 patients[ J]. Acta Ophthalmol, 2019, 97(3): e390-e396.
19、Ivan D, Prieto VG, Esmaeli B, et al. Epidermal growth factor receptor
(EGFR) expression in periocular and extraocular sebaceous
carcinoma[ J]. J Cutan Pathol, 2010, 37(2): 231-236.Ivan D, Prieto VG, Esmaeli B, et al. Epidermal growth factor receptor
(EGFR) expression in periocular and extraocular sebaceous
carcinoma[ J]. J Cutan Pathol, 2010, 37(2): 231-236.
20、Lee MJ, Kim N, Choung HK, et al. Increased gene copy number
of HER2 and concordant protein overexpression found in a subset
of eyelid sebaceous gland carcinoma indicate HER2 as a potential
therapeutic target[ J]. J Cancer Res Clin Oncol, 2016, 142(1):
125-133.Lee MJ, Kim N, Choung HK, et al. Increased gene copy number
of HER2 and concordant protein overexpression found in a subset
of eyelid sebaceous gland carcinoma indicate HER2 as a potential
therapeutic target[ J]. J Cancer Res Clin Oncol, 2016, 142(1):
125-133.
